AU2018217271A1 — Stable parenteral DNJ compositions
Assigned to Amicus Therapeutics Inc · Expires 2018-09-06 · 8y expired
What this patent protects
The present invention provides a stable pharmaceutical composition comprising: a) an active agent selected from 1 -deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and b) a buffer, wherein the stable pharmaceutical composition is capable of b…
USPTO Abstract
The present invention provides a stable pharmaceutical composition comprising: a) an active agent selected from 1 -deoxynojirimycin, a pharmaceutically acceptable salt thereof, or a derivative thereof, and b) a buffer, wherein the stable pharmaceutical composition is capable of being parenterally administered to a human without deleterious health effects. WO 2014/110270 PCT/US2014/010891 cov 4- f4-A E o0 u o N N ------------ oC N n oo -C S
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.